[
    [
        {
            "time": "2018-07-01",
            "original_text": "Mairs and Power Growth Fund 2nd-Quarter Shareholder Letter",
            "features": {
                "keywords": [
                    "Mairs",
                    "Power Growth Fund",
                    "Shareholder Letter"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Mairs and Power Growth Fund 2nd-Quarter Shareholder Letter",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-05",
            "original_text": "6 Declining Stocks in Gurus' Portfolios",
            "features": {
                "keywords": [
                    "Declining Stocks",
                    "Gurus",
                    "Portfolios"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "various"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "6 Declining Stocks in Gurus' Portfolios",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-06",
            "original_text": "A Big Cancer Conference Starts Tomorrow. Here’s What It Means for Merck, Bristol-Myers and Other Drug Stocks.",
            "features": {
                "keywords": [
                    "Cancer Conference",
                    "Merck",
                    "Bristol-Myers",
                    "Drug Stocks"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A Big Cancer Conference Starts Tomorrow. Here’s What It Means for Merck, Bristol-Myers and Other Drug Stocks.",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-07",
            "original_text": "Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Dividend Stock",
                    "Portfolio"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-07-08",
            "original_text": "Incyte Treats First Patient in Phase III Vitiligo Study",
            "features": {
                "keywords": [
                    "Incyte",
                    "Phase III",
                    "Vitiligo Study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Incyte Treats First Patient in Phase III Vitiligo Study",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]